1. Introduction {#s0005}
===============

Klinefelter syndrome (KS) (47, XXY) affects 1 out of 660 men, making it the most common sex-chromosome aneuploidy in males ([@bb0055]). KS is associated with verbal learning disabilities ([@bb0280]), impairments in memory ([@bb0115]) and executive functions ([@bb0200]) and the general intelligence has been found to range between sub-average and average levels ([@bb0025; @bb0045; @bb0115; @bb0135; @bb0140; @bb0155; @bb0175; @bb0200; @bb0215; @bb0255; @bb0320; @bb0330; @bb0340; @bb0345]). A vulnerability is also present in KS towards psychiatric diseases such as depression, anxiety, schizophrenia, attention deficit hyperactivity disorder and autism spectrum diseases ([@bb0060]). The most prominent hormonal abnormality in KS is hypergonadotropic hypogonadism. Brain imaging studies of KS may contribute not only to the understanding of the neurobiology underlying the cognitive disabilities and the increased risk of psychiatric diseases that have not been delineated yet in KS ([@bb0065]), but also to an understanding of X-chromosome linked mechanisms underlying cognitive disabilities and psychiatric diseases in general.

Studies using brain imaging techniques in boys and adults with KS have found significant volume differences in multiple brain regions, but the results are rather discordant. Total brain volume (TBV) was reported by some studies to be reduced ([@bb0105; @bb0140; @bb0305; @bb0360]) while others report no difference ([@bb0065; @bb0260]). Regarding brain ventricles, these have been reported to be enlarged in some studies ([@bb0140; @bb0175; @bb0305; @bb0360]) while others have found no volumetric differences ([@bb0105; @bb0260]). Furthermore, discrepant data also exist regarding lobar volumes including the temporal lobes ([@bb0065; @bb0105; @bb0140; @bb0175; @bb0260; @bb0305; @bb0360]), frontal lobes ([@bb0065; @bb0105; @bb0140; @bb0175; @bb0360]) and parietal lobes ([@bb0140; @bb0175; @bb0305; @bb0360]) and the volumes of more specific brain structures such as amygdala and hippocampus ([@bb0065; @bb0105; @bb0175; @bb0260; @bb0295; @bb0305; @bb0360]) and the caudate nuclei ([@bb0065; @bb0140; @bb0360]) with some studies reporting smaller volumes for these structures while other studies report these to be of normal size. All studies that have been published so far had small sample sizes. Moreover, investigators used different volumetric neuroimaging techniques and there was considerable variability in studied sample age as well as the frequency of testosterone treatment ([@bb0315]).

As KS is associated with hypergonadotropic hypogonadism, many of the KS patients start testosterone therapy around puberty or later in life when the syndrome is diagnosed, often with a substantial delay and a resulting long period of exposure to hypogonadism. Sex hormones and especially testosterone may have both an 'organizational effect' and an 'activational effect' on neural pathways ([@bb0085; @bb0265]), which have raised the question whether testosterone therapy in KS patients could have a modulating effect on brain volume. In one study ([@bb0260]) KS patients not receiving testosterone were found to have smaller temporal volumes than controls, while KS patients receiving testosterone treatment did not. Other investigators ([@bb0175]) found no significant effect of testosterone treatment on brain volumes. Another area of uncertainty is the possible correlation between the neuropsychological profile in KS and results of structural brain imaging. The few studies that attempted to investigate this either had very small sample sizes ([@bb0105; @bb0175; @bb0260; @bb0360]) and/or involved very few neuropsychological tests ([@bb0065; @bb0260; @bb0360]).

In the present study, we studied brain volumes in a large sample of 65 KS patients using voxel-based morphometry (VBM), and correlated these data to scores on a comprehensive neuropsychological test battery. The presented data do not support a correlation between morphometric indices and neuropsychological parameters or testosterone treatment.

2. Materials and methods {#s0010}
========================

2.1. Participants {#s0015}
-----------------

Seventy-nine patients with verified KS recruited from endocrinology, genetics and fertility clinics in Denmark agreed to participate in the study. Seventy-seven of seventy-nine KS patients were registered by the Danish Cytogenetic Central Register in Denmark and the karyotype was confirmed by the register. Two of the KS patients were not registered in register and were karyotyped using standard techniques to verify their KS diagnose. Inclusion criteria were ages between 18 and 60 years and signed informed consent. Exclusion criteria were i) a history of neurological disease or head injury more severe than simple concussion, ii) current substance abuse, iii) color blindness or iiii) metal implants not suitable for magnetic resonance (MR) imaging. Subsequently, 14 of the KS patients were excluded from the study due to either anatomical scans with motion artifacts (n = 1), missing scan images (n = 1), developing claustrophobia inside the scanner (n = 3), too large body-proportion to enter the scanner (n = 2), unknown metal splinter in finger (n = 1), chronic solvent-induced encephalopathy diagnosis (n = 1) and use of cannabis within the last month before examination (n = 5), thus resulting in 65 patients with KS eligible for the study (mean age 36.8 ± 10.5 (SD) years). Sixty two (95%) of the KS patients had 47,XXY karyotype and 3 (5%) had chromosomal mosaicism (1 patient had 88% 47,XXY/10% 46,XY/2% 48,XXXY; 1 patient with 90% 47,XXY/10% 46,XXY; 1 patient with 40--60% 47,XXY/40--60% 46, XY). At the time of participation, 44 (68%) of the KS patients received testosterone treatment (intramuscular testosterone injections (n = 38), oral testosterone (n = 1), cutaneous testosterone gel (n = 5)). Fourteen of the 21 KS patients (67%) who did not receive testosterone treatment had never received treatment with testosterone, while six had received testosterone therapy in the past for an average time period of 35.3 months (range: 10 month--7 years) and one KS patients had received testosterone for an unspecified period when he was younger. Sixty of the KS patients were right-handed, 3 were left-handed and 2 were ambidextrous.

Sixty five male controls matched for age and education were recruited through advertisement in local hospitals, in local newspapers, at local work services, among volunteer fire fighters, at citizen service offices and at local libraries. Karyotyping on the 73 controls was not performed, but none of these showed signs of more than one X-chromosome in androgen receptor polymorphism or X-chromosome microsatellite analysis. None of the controls received or had received treatment with testosterone. Fifty-seven of the controls were right-handed and 8 were left-handed. Inclusion and exclusion criteria were the same as the criteria for KS patients mentioned above.

All participants received oral and written information about the study before giving their written consent. The study was approved by the Danish Data Protection Agency and local ethics committee (Region Midtjylland, Denmark number M-20080238) and registered at ClinicalTrials.gov (Clinical trial [NCT00999310](ctgov:NCT00999310){#ir0015}).

2.2. Cognitive assessment {#s0020}
-------------------------

Participants were administered a 3-h battery of standardized cognitive tests designed to assess major cognitive functions. Administration and scoring of the tests were done by trained research assistants under supervision of a psychologist and a senior specialist in clinical neuropsychology. The test battery consisted of the following cognitive domains and tests:▪Processing speed; tests included Trail Making A and B ([@bb0285]) and the Coding subtest of the Wechsler Adult Intelligence Scale --- third edition (WAIS-III) ([@bb0370]).▪Working memory; tests included Digit Span (DS) and Letter--Number Sequencing (LN) subtests of WAIS-III ([@bb0370]).▪Visual/spatial construction and performance; tests included the Copy subtest of the Rey Complex Figure Test and Recognition Trial (RCFT) ([@bb0240]) and the Block Design (BD) and the Matrix Reasoning (MR) subtests of WAIS-III ([@bb0370]).▪Visual memory and learning; tests included the Immediate Recall and Delayed Recall subtests of RCFT ([@bb0240]).▪Verbal memory and learning; tests included Rey Auditory Verbal Learning Test (RAVL) ([@bb0250]).▪Verbal fluency and comprehension; tests included the Similarities (S) and the Vocabulary (V) subtests of WAIS-III ([@bb0370]), Sentence Repetition ([@bb0310]), and Verbal fluency tests (animals and words by initial letter N, S and F. Score was sum of all 4 categories) ([@bb0220]).▪Response inhibition; test included the Stroop Color and Word Test (SCWT) ([@bb0145]).▪Executive function; test included Tower of London (TOL) ([@bb0095]) and Wisconsin Card Sorting tests (WCST) ([@bb0170]).▪Intelligence; Full scale Intelligence Quotient (FSIQ), Verbal Intelligence Quotient (VIQ) and Performance Intelligence Quotient (PIQ) were determined by the following regression equation derived from summary statistics data e.g. mean, standard deviation, correlations of the subtest from the WAIS-III Danish reference material ([@bb0370]): FSIQ = 40.21 + (1.13 × S) + (1.38 × MR) + (2.10 × V) + (1.35 × BD); VIQ = 50.91 + (2.14 × S) + (2.76 × V); PIQ = 49.86 + (2.57 × MR) + (2.47 × BD).

2.3. Psychological questionnaires {#s0095}
---------------------------------

A week prior to the study participants received three self-administered psychological questionnaires to be completed before the day of participation. These included questions concerning three psychological domains:▪Psychological distress; SCL-8 (mental illness) ([@bb0120; @bb0125; @bb0130]), SCL-DEP6 (depression) ([@bb0080; @bb0075]) and SCL-ANX4 (anxiety) ([@bb0080; @bb0075]) derived from the Symptom Checklist (SCL-90) ([@bb0040; @bb0110]) used to measure psychological distress.▪Autism traits; Autism Spectrum Quotient (AQ) ([@bb0035]) measuring autistic traits.▪Personality; Revised NEO Personality Inventory (NEO PI-R), short form ([@bb0090]). A 60-item measure of the Big Five personality traits --- neuroticism, extraversion, openness to experience, agreeableness and conscientiousness.

2.4. Magnetic resonance imaging (MRI) {#s0100}
-------------------------------------

### 2.4.1. MRI acquisition {#s0025}

A 3-T General Electrics Medical systems (Milwaukee, WI USA) MR system with a standard headcoil was used to acquire high-resolution 3D GR contiguous T1-weighted anatomical scans, consisting of 256 × 256 × 134 voxels with a 0.94 × 0.94 × 1.2 mm^3^ voxel size, obtained with a TR of 6.552 ms, a 2.824 ms TE and a 14° flip angle.

### 2.4.2. MRI data pre-processing {#s0035}

Voxel-based morphometry (VBM) analysis was performed using Statistical Parametric Mapping (SPM8) (<http://www.fil.ion.ucl.ac.uk/spm/>). T1-weighted scan images were converted from DICOM format to NIfTI format and these images were manually inspected to rule out large scale and focal brain abnormalities as well as acquisition artifacts. In addition, images were manually co-registered to the anterior commissure--posterior commissure axis in order to provide optimal conditions for automated pre-processing and analysis. Images were classified into gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) using the unified segmentation tool in SPM8 ([@bb0020]) with very light bias regularization (0.0001, 60 mm FWHM cutoff) and an affine transformation to the ICBM space template (European brains). For analysis of global brain volumes, we considered the preprocessed tissue classification probability in each voxel to be an estimate of regional GM/WM/CSF volume. Global differences in GM, WM, CFS and total brain volumes between KS patients and controls were analyzed using two-sample t-tests on the sum of tissue classification probabilities across all voxels for a given structure type. Age effect on global brain volumes was analyzed by Spearmann correlation within and between groups. We did not find any significant effect of age on global brain volumes (all p-values \> 0.05). To enable voxel-wise comparisons, GM images were further normalized to the templates generated from Diffeomorphic Anatomical Registration using Exponentiated Lie algebra (DARTEL) ([@bb0015]). A study specific template was generated using DARTEL to minimize between scan variations ([@bb0190]). The template was made using the complete set (n = 130) of segmented GM and WM scans and linear elastic energy regularization together with all DARTEL default settings. Finally, the segmented and normalized images were smoothed with a default 8 mm FWHM Gaussian filter.

### 2.4.3. Classification analysis {#s0040}

Classification analysis was based on the same images as those used in the SPM analysis. Additionally, each subject\'s image was scaled by the global brain volume (GM + WM) in order to parallel the scaling in the univariate SPM analysis. The classification analysis was performed as a whole brain analysis, using the same masking as in the SPM analysis. A binary classification task was set up to classify KS patients vs. controls. For classification we used Fisher\'s linear discriminant analysis (FDA) which is a well known method that considers dimensionality reduction and classification jointly. FDA seeks to find an optimal subspace where the projected class means are separated the most in terms of variance ([@bb0160; @bb0165]). We used a version of FDA also referred to as regularized/penalized discriminant analysis ([@bb0165]) in order to control for model over-fitting and to ensure model uniqueness. On top of the FDA basis we implemented a simple nearest mean classifier to evaluate the prediction accuracy. Leave-one-out (LOO) cross validation was used to evaluate the prediction accuracy: One subject was routinely held out from the training sample, and the FDA model was trained on the remaining 129 subjects. The trained model was then used to predict the category of the out-of-sample subject. This was repeated for all subjects. Selection of the regularization parameter was based only on training subjects in a nested LOO cross validation loop. To interpret/visualize the FDA model we use the model weight vector ([@bb0185]). To estimate a stable representation of the underlying spatial brain pattern we used the NPAIRS resampling framework ([@bb0325]). This resampling analysis provides a reproducible brain map (rSPM) that is on an approximate Z-score scale. Finally, the rSPM was thresholded according to correction for multiple comparisons by the false discovery rate (FDR) procedure ([@bb0050]). For further details on model visualization and the NPAIRS resampling analysis see [@bb0325] and [@bb0275].

2.5. Statistical analysis {#s0045}
-------------------------

Voxel-based statistical analyses were conducted using a general linear model approach. Correction for global brain volume (GM + WM) was done using proportional scaling. Initial analyses included age as a covariate, however no significant voxel-wise effect was seen (all p-values \> 0.7 FWE corrected) and the age covariate was removed from the final analysis. Analysis of GM was performed using an explicit mask, including all voxels with a probability above 5% for the given tissue class. Two between-group contrasts were defined for GM: KS \> C and C \> KS and tested with two-sample *t*-test. P \< 0.05 was used as significance threshold, whole brain corrected for family-wise error and cluster size \> 20 voxels. Anatomical regions were located using WFU (Wake Forest University School of Medicine) Pickatlas referencing the AAL atlas ([@bb0335]).

To test the relationship between regional brain volumes and psychological and cognitive variables, we first applied principal component analyses (PCA) ([@bb1000]) to the tests in each individual psychological and cognitive domain. This was done to reduce the dimensionality of the psychological and cognitive variables. The PCA analysis was performed by STATA (StataCorp, College Station, TX). The first component extracted from each domain was included as a covariate in the general linear model in SPM8 (see [Supplementary material](#ec0005){ref-type="supplementary-material"} for details about the covariates). Multiple regressions were used to assess the variation in regional brain volume attributable to the three psychological and ten cognitive domains. P \< 0.05 was used as significant threshold, corrected for family-wise error. Spearman\'s rank correlation coefficient was used to test the relationship between global brain volumes and the three psychological and the ten cognitive domains, employing Bonferroni\'s adjustment for multiple testing. Between-group differences in psychological and cognitive test scores and demographic variables were analyzed in SPSS (SPSS Inc., Chicago, IL, USA) using independent two-sample t-tests if data met the criteria for normal distribution; otherwise data were analyzed with non-parametric Mann Whitney test. Chi-square tests were used for nominal variables.

To test the relationship between regional brain volumes and psychological and cognitive variables, we first applied principal component analyses (PCA) ([@bb1000]) to the tests in each individual psychological and cognitive domain. This was done to reduce the dimensionality of the psychological and cognitive variables. The PCA analysis was performed by STATA (StataCorp, College Station, TX). The first component extracted from each domain was included as a covariate in the general linear model in SPM8 (see Supplementary material for details about the covariates). Multiple regressions were used to assess the variation in regional brain volume attributable to the three psychological and ten cognitive domains. P \< 0.05 was used as significant threshold, corrected for family-wise error. Spearman\'s rank correlation coefficient was used to test the relationship between global brain volumes and the three psychological and the ten cognitive domains, employing Bonferroni\'s adjustment for multiple testing. Between-group differences in psychological and cognitive test scores and demographic variables were analyzed in SPSS (SPSS Inc., Chicago, IL, USA) using independent two-sample t-tests if data met the criteria for normal distribution; otherwise data were analyzed with non-parametric Mann Whitney test. Chi-square tests were used for nominal variables.

3. Results {#s0050}
==========

3.1. Demographic and psychological characteristics {#s0055}
--------------------------------------------------

Demographic and psychological characteristics of participants are presented in [Table 1](#t0005){ref-type="table"}. There was no difference with respect to age and educational level between KS patients and controls. KS patients reported significantly more symptoms of psychological distress. Furthermore, KS patients had a different personality profile with a significantly higher level of neuroticism, and a significantly lower level of extraversion, agreeableness and conscientiousness. The KS patients also scored significantly higher on all subscales of the Autism Spectrum Quotient test, except the attention to detail subscale.

3.2. Cognitive test results {#s0060}
---------------------------

The cognitive test scores ([Table 2](#t0010){ref-type="table"}) showed that the KS patients had significantly lower full scale IQ, verbal IQ and performance IQ. Furthermore, KS patients had significantly slower processing speed, lower working memory capacity, significantly decreased verbal abilities and poorer response inhibition compared to controls. No differences in visual abilities were found between the two groups, except for the two tests influenced by intelligence (WAIS-BD, WAIS-MR). As for executive functions data from the TOL test indicated poorer planning ability among KS patients (significantly higher total move score and a significantly lower correct score), and reduced mental flexibility as measured with the WCST (KS patients used significantly more cards, completed significantly fewer categories with more errors and perseverative responses).

3.3. MRI data {#s0065}
-------------

Significantly smaller total brain volume (TBV), total gray matter volume (GMV) and total white matter volume (WMV) were found in KS patients compared to controls, whereas there was no significant difference in CSF volume ([Table 3](#t0015){ref-type="table"}). Asymmetries in left and right GM volume were similar between the two groups (GMV_dif~KS~ = − 11.2 ± 4.2 mL; GMV_dif~c~ = − 11.6 ± 4.1; p = 0.625). There were no significant differences in TBV, GMV, WMV or CSF between testosterone treated KS (T-KS) and untreated KS (U-KS) patients. VBM-analysis ([Table 4](#t0020){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}) showed that KS patients had significantly decreased GMV bilaterally in insula, putamen, caudate, hippocampus, amygdala, temporal pole and frontal inferior orbita compared to controls. Additionally, the right cerebellum and parahippocampal gyrus was reduced in KS patients. KS patients had significantly larger volumes in regions of the postcentral gyrus, inferior and superior parietal lobules and precuneus, bilaterally, compared to controls ([Table 4](#t0020){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}). We did not find any significant difference in regional GMV between untreated and treated KS patients (data not shown). The classification analysis correctly discriminated KS patients from controls with 96.9% accuracy (p \< 0.001 using nonparametric permutation) (four controls were misclassified). [Fig. 2](#f0010){ref-type="fig"} shows the reproducible brain map (rSPM) extracted within the NPAIRS resampling framework. The rSPM represents a stable pattern of brain locations supporting discriminative information to the classifier. The rSPM was thresholded according to p \< 0.05 FDR correction for multiple testing. Hot and cold colors represent positive and negative Z-scores respectively. The interpretation of the map is as follows: Increasing the signal locally in cold areas will make a particular brain scan more likely to be classified as a KS patients, these area include the same brain regions and lobes as found we found by VBM analysis. Conversely, increasing the signal locally in warm areas will make a brain scan more likely to be classified as a control, these areas include the same brain areas as found by primary VBM analysis.

3.4. Correlation between global and regional brain volume and neuropsychological performance {#s0070}
--------------------------------------------------------------------------------------------

In the initial across group analyses, we found a significant positive correlation between intelligence and GMV (rho = 0.18, p = 0.04), between intelligence and WMV (rho = 0.20, p = 0.02) and between visual performance and WMV (rho = 0.23, p = 0.009) in the 130 subject group. Within controls, we found a positive significant correlation between visual performance and GMV (rho = 0.26, p = 0.04) and between visual performance and WMV (rho = 0.30, p = 0.02), and a significant negative correlation between processing speed and GMV (rho = − 0.30, p = 0.02). No correlations were found within the group of KS patients. In the subsequent analyses which included Bonferroni adjustment, we found no significant correlation between psychological and cognitive domains and global GMV, WMV and CSF in the 130 subject group or within controls separately. Furthermore, we did not find any significant correlations between voxel-wise regional brain volumes and the 3 psychological and 10 cognitive domains ([Table 5](#t0025){ref-type="table"}).

4. Discussion {#s0075}
=============

The present study documents significantly reduced global and regional brain volumes in KS patients. Based on the brain scans we could predict a KS diagnosis with 96.9% accuracy. We did not find any significant correlation between the reduced brain volumes and neuropsychological outcome measures, nor did we demonstrate any significant effect of testosterone treatment on brain volumes.

Globally, KS patients had significantly smaller TBV, in agreement with previous studies ([@bb0065; @bb0105; @bb0140; @bb0305; @bb0365]), and significantly smaller GMV and WMV. Other VBM studies of KS patients demonstrate similar results, i.e., either a significantly decreased WMV and GMV in boys and adolescents ([@bb0305]), or a trend towards decreased WMV (p = 0.059) and GMV (p = 0.07) in boys ([@bb0065]). However, studies using ROI and LowD techniques found only an isolated GMV decrease in boys and adolescents ([@bb0140]) or an isolated WMV decrease in adults ([@bb0290]). No volumetric difference in CSF was found in our study. No study has earlier reported CSF measurements in KS patients. Studies using ROI have found either enlarged lateral ventricles ([@bb0140; @bb0305; @bb0365]) or no volumetric differences ([@bb0105; @bb0260]). As we found no volumetric difference in CSF, a putatively larger lateral ventricle would require smaller CFS volumes in other brain regions which seems unlikely. In accordance with [@bb0290] we found no difference in left and right hemisphere global GMV and WMV between KS patients and controls.

The concordance between our findings of changes in TBV, GMV and WMV in our adult group of KS patients and other VBM studies of boys and adolescents with KS, indicates that these differences in brain volumes probably develop during fetal life or early childhood, either due to the gene dosage of having an extra X-chromosome or to differences in endogenous testosterone level. Testosterone influences brain development in the human fetus ([@bb0195]). If -- and to what degree -- prenatal and postnatal testosterone levels are affected in KS is uncertain. KS is associated with an increased prevalence of microphallus and cryptorchidism ([@bb0300]) indicating low intrauterine testosterone levels. However, studies in KS neonates report either decreased or normal/high testosterone levels ([@bb0005; @bb0210]). A recent study actually does suggest that intrauterine testosterone is decreased in KS fetuses ([@bb0230]). The brain size in girls with congenital adrenal hyperplasia exposed to excessive testosterone, prenatally, is not larger than brains in female controls, indicating that testosterone prenatally does not determine global brain size in girls ([@bb0235]). In addition, we found no significant difference in global brain sizes between testosterone treated and untreated KS patients in accordance with previous studies ([@bb0175; @bb0260]), indicating that exogenous testosterone does not affect global brain volumes in adult KS patients either. In conclusion, the observed difference in global brain size seems to be an inherited trait specific to KS, but it remains to be determined whether genetic or endocrine factors or a combination of these factors are to blame. This is supported by a study of brain volumes in females with 47,XXX in which reduced brain volume has been demonstrated ([@bb0360]).

We observed pervasive differences in regional brain volumes in brain regions involved in cognitive functions. We found a significantly smaller volume of the caudate nucleus and putamen among KS patients, also observed by [@bb0140] but not in other studies ([@bb0305; @bb0365]). The caudate nucleus is part of the circuits involved in learning ([@bb0270]) and executive functions ([@bb0010]). Smaller caudate volume has been found to be associated with ADHD ([@bb0070]), which is seen with an increased prevalence in KS ([@bb0060]). In accordance with others ([@bb0105; @bb0140; @bb0260; @bb0305]), we demonstrated regional volumetric differences in the temporal and frontal lobes, regions involved in adaptive learning and social functions ([@bb0205]). We also observed decreased hippocampal and parahippocampal volumes in KS patients, which was also reported by [@bb0065]. Hippocampal/parahippocampal regions are involved in memory processing ([@bb0375]) known to be affected in KS ([@bb0115]). Decreased amygdala volume in KS patients as we found, has been reported previously ([@bb0065; @bb0260; @bb0295; @bb0305]). Amygdala is part of the limbic system which is involved in social and emotional processing ([@bb0355]), which is known to be affected in KS patients ([@bb0345]). Furthermore, we found a significantly smaller insula in KS patients. Reduced volume of the insula has been associated with impaired social communication ([@bb0030]), impairments which have also been described in KS patients ([@bb0345]).

The regional volume abnormalities seen in KS have been proposed to be due to either hypogonadism or gene dosage effect. A recently published study found fetal testosterone to influence gray matter volume in specific temporal, parietal and orbitofrontal areas ([@bb0225]). We found no volumetric GM abnormalities in these specific brain regions in our KS patients, indicating that the regional volumetric abnormalities seen in KS most likely are due to the gene dosage effect of the extra X-chromosome and not directly to the effects of low testosterone. The hypothesis that an altered X-chromosome dosage can influence regional brain volume is supported by a study who found evidence of dosage-sensitive X-linked locus influencing the volume of amygdala ([@bb0150]). We found an effect in the same region, albeit extended to the entire medial and frontal temporal lobe. Furthermore, women with Turner syndrome who have only one X-chromosome, have reduced the volume of the parietal lobe and increased the volume of the temporal lobe ([@bb0100; @bb0180]), indicating that X-chromosome gene dosage may influence the size of the parietal and temporal lobes. Contrary to this there is evidence that testosterone has an organizational effect on brain volumes. A recent voxel-based morphometry study reported that gray matter volume in parahippocampal gyri and putamen were increased in boys with early excess of androgen secretion compared to healthy age-matched boys ([@bb0245]). Our finding of decreased gray matter volume in the same area in KS patients, a syndrome associated with androgen insufficiency, is in line with these findings, suggesting an influence of androgen on brain regions such as the parahippocampal area and putamen and perhaps a more general organizational effect on the brain.

We aimed to associate the neuroanatomical phenotype with the neuropsychological phenotype seen in KS. It has long been the perception that regional volumetric abnormalities associated with KS underlie the neuropsychological phenotype seen in KS, although few studies have investigated this. We did not find any correlation between neuropsychological test scores and regional brain volumes. This lack of correlation has also been observed in four out of the five existing publications, although these four publications suffer from a limited number of participants (n = 10--31) and a limited neuropsychological test battery ([@bb0065; @bb0105; @bb0260; @bb0365]). The only published study in KS using a thorough neuropsychological test battery found an inverse correlation between ventricular volume and processing speed and executive function, whereas left temporal lobe volume showed a positive correlation with language scores and processing speed in right-handed subjects ([@bb0175]). These analyses, however, may reflect known between-group effects, as the analysis was done on the KS patients and controls combined ([@bb0315]). The lack of correlation between brain volume and neuropsychological test scores found within our large sample of KS patients indicates that the explanation of the neuropsychological deficits in KS may be related to the micro-architecture, rather than the mesoscopic anatomical brain level investigated using VBM. Our data indicate that the neuroanatomical etiology of the neuropsychological phenotype of KS is much more complicated than just simply differences in volumetric measurements. This complexity is mirrored in well-known gender difference in GMV. Although females on average have 10% smaller GMV, it is very difficult to point to any significant neuropsychological effects of this ([@bb0350]). To understand the neuroanatomical etiologies of the neuropsychological phenotype, we need to investigate the brain by functional scans and investigate the interaction between behavior, brain function and the possible relation to X-linked genes and changes in gene expression.

4.1. Strength {#s0080}
-------------

This study is the largest study conducted investigating brain volumes in KS participants. Our KS patients and controls were carefully matched on age and educational background. We used a comprehensive neuropsychological test battery. Compared to the ROI, the VBM-method is an objective method not biased by subjectivity. Furthermore, the VBM-method allows investigation of the entire brain, not just of easily quantified brain structures.

4.2. Limitations {#s0085}
----------------

Our data concerning the effect of testosterone on global brain volumes are weakened by a lack of standardization of duration and pharmaceutical form of testosterone therapy and the age when initiating testosterone therapy. The lack of correlation between brain volumes and neuropsychological test score could be due to the fact that significant changes in neuropsychological test scores are too weak a measurement to correlate to brain volume in general, or that the neuropsychological test score are influenced by other parameters (such as depression) blurring the test score.

5. Conclusion {#s0090}
=============

In summary, we present global and regional brain volumetric measurements and their possible associations to the neuropsychological phenotype and testosterone therapy in the largest cohort of KS patients to date. Our data suggest that KS is associated with global and regional brain volumetric changes, and that these changes probably are due to a gene dosage effect rather than hypogonadism. We did not find evidence that testosterone therapy affects brain volume in KS or that the neuropsychological phenotype can be explained by differences in brain volume.

The following is the supplementary data related to this article.Supplementary Table 1Principal component analysis: Domains, tests included and 1.component. WAIS-III, Wechsler Adult Intelligence Scale --- third edition; RCFT, Rey Complex Figure Test and Recognition Trial; RAVLT, Rey Auditory Verbal Learning Test; SCWT, Stroop Color and Word Test; WCST, Winconsin Card Sorting Test; TOL, Tower of London Test.

Supplementary data to this article can be found online at [http://dx.doi.org/10.1016/j.nicl.2013.10.013](10.1016/j.nicl.2013.10.013){#ir0025}.
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![Coronal slice representation of gray matter differences between KS patients and controls. T-map displaying significant gray matter cluster differences between the KS patients and controls (p = 0.05, FWE corrected) is overlaid brain template. Significant gray matter clusters were KS \< controls is displayed in orange-red colors. Significant gray matter clusters were KS \> controls is shown in green-blue colors (t (df), df = 128).](gr1){#f0005}

![Whole-brain representation of classification analysis (reproducible) brain map (p \< 0.05FDR). Increasing the signal locally in cold areas will make a particular brain scan more likely to be classified as a KS patient. Increasing the signal locally in warm areas will make a brain scan more likely to be classified as a control.](gr2){#f0010}

###### 

Age, education and psychological data. Data are median (total range) or mean ± SD. SCL, Symptoms Check List; NEO PI-R, Revised NEO Personality Inventory; AQ, Autism Spectrum Quotient.

                            KS (n = 65)   Controls (n = 65)   p-Value KS vs. controls
  ------------------------- ------------- ------------------- -------------------------
  Age (yr)                  36.8 ± 10.5   36.8 ± 10.3         0.96
  Education (yr)            13 (7--18)    13 (8--18)          0.94
                                                              
  *SCL*                                                       
  DEP4 (depression)         3 (0--20)     1 (0--14)           0.01
  ANX6 (anxiety)            2 (0--15)     2 (0--8)            0.006
  SCL-8 (mental disorder)   6 (0--28)     2.5 (0--19)         0.001
                                                              
  *NEO PI-R*                                                  
  Neuroticism               63 (42--78)   50 (31--70)         \< 0.001
  Extraversion              44 (22--69)   55 (22--78)         \< 0.001
  Openness                  51 (28--71)   46 (22--70)         0.23
  Agreeableness             51 (22--67)   56 (32--74)         0.002
  Conscientiousness         45 (22--71)   51 (22--71)         0.02
                                                              
  *AQ*                                                        
  Total                     19 (9--41)    14 (7--28)          \< 0.001
  Communication skills      3 (0--10)     2 (0--6)            0.01
  Social skills             3 (0--10)     1 (0--9)            \< 0.001
  Imagination               4 (0--10)     3 (0--8)            \< 0.001
  Attention to detail       4 (0--9)      4 (0--8)            0.42
  Attention switching       4 (0--10)     3 (0--9)            0.007

###### 

Neurocognitive ability in patients with Klinefelter syndrome and controls. IQ, intelligence quotient; WAIS-III, Wechsler Adult Intelligence Scale --- third edition; WAIS-III C, WAIS-III Coding; TMA, Trail Making A; TMB, Trail Making B; WAIS-III DS, WAIS-III Digit Span; WAIS-III LN, WAIS-III Letter-Number Sequencing; RCFT, Rey Complex Figure Test and Recognition Trail; WAIS-III BD, WAIS-III Block Design; WAIS-III MR, WAIS-III Matrix Reasoning; RAVL, Rey Auditory Verbal Learning Test; WAIS-III V, WAIS-III Vocabulary; WAIS-III S, WAIS-III Similarities; SCWT diff, Stroop Color and Word Test Difference Score; TOL, Tower of London; WCST, Wisconsin Card Sorting Test; Data are medians (total range) or means ± SD.

                                                                  KS (n = 65)         Controls (n = 65)   p-Value KS vs. controls
  --------------------------------------------------------------- ------------------- ------------------- -------------------------
  *Intelligence*                                                                                          
  Full scale IQ                                                   87.8 ± 12.0         103.7 ± 11.3        \< 0.001
  Verbal IQ                                                       84.7 ± 12.3         100.8 ± 11.7        \< 0.001
  Performance IQ                                                  96.7 ± 13.2         106.2 ± 10.9        \< 0.001
                                                                                                          
  *Processing speed*                                                                                      
  WAIS-III C                                                      57 (31--91)         71 (39--112)        \< 0.001
  TMA (sec.)[a](#tf0005){ref-type="table-fn"}                     29 (26--80)         23 (12--64)         \< 0.001
  TMB (sec.)[a](#tf0005){ref-type="table-fn"}                     77 (25--205)        62 (32--208)        0.002
                                                                                                          
  *Working memory*                                                                                        
  WAIS-III DS                                                     13 (8--22)          15 (10--24)         \< 0.001
  WAIS-III LN                                                     9 (4--18)           11 (7--18)          0.005
                                                                                                          
  *Visual performance*                                                                                    
  RCFT Copy                                                       33 (22--36)         33 (22--36)         0.86
  WAIS-III BD                                                     43 (19--66)         55 (12--66)         \< 0.001
  WAIS-III MR                                                     18 (5--25)          21 (7--25)          \< 0.001
                                                                                                          
  *Visual memory and learning*                                                                            
  RCFT immediate recall                                           22.5 (9.5--33.0)    22.5 (9.0--34.0)    0.49
  RCFT delayed recall                                             21.5 (11.5--33.0)   21.5 (7.5--34.0)    0.84
                                                                                                          
  *Verbal memory and learning*                                                                            
  RAVLT 1.trail                                                   5 (2--11)           6 (2--12)           0.003
  RAVLT total                                                     43 (21--66)         51 (29--70)         \< 0.001
  RAVL delayed recall                                             10 (0--15)          11 (5--15)          0.13
                                                                                                          
  *Verbal performance*                                                                                    
  Verbal fluency                                                  51 (21--94)         67 (35--107)        \< 0.001
  WAIS-III S                                                      17.5 (8.0--26.0)    23 (11--31)         \< 0.001
  WAIS-III V                                                      24.5 (8.0--49.0)    37 (12--57)         \< 0.001
  Sentence span                                                   15 (10--21)         17.5 (13.0--22.0)   \< 0.001
                                                                                                          
  *Response inhibition*                                                                                   
  SCWT diff                                                       1.72 ± 7.48         3.28 ± 8.3          \< 0.001
                                                                                                          
  *Executive function*                                                                                    
  WCST cards administered[a](#tf0005){ref-type="table-fn"}        113 (70--128)       83 (70--128)        \< 0.001
  WCST errors (%)[a](#tf0005){ref-type="table-fn"}                26 (11--62)         18(11--58)          \< 0.001
  WCST persev. responses (%)[a](#tf0005){ref-type="table-fn"}     15 (5--40)          9 (5--34)           \< 0.001
  WCST categories completed                                       6 (1--6)            6 (1--6)            0.007
  WCST failure to maintain set[a](#tf0005){ref-type="table-fn"}   1 (0--4)            0 (0--5)            0.01
  TOL total move score[a](#tf0005){ref-type="table-fn"}           26 (0--67)          16 (0--55)          0.003
  TOL total correct score                                         5 (0--10)           6 (1--10)           0.005

Lower score means better performance.

###### 

Brain volumetric measures in KS patients and controls. Data are mean ± SD (p \< 0.05, uncorrected). GMV, gray matter volume; WMV, white matter volume; CSF, Cerebrospinal fluid; U-KS, untreated KS males; T-KS, testosterone treated KS males.

                                   U-KS           T-KS           KS             Controls       p-Value   t-Value             
  -------------------------------- -------------- -------------- -------------- -------------- --------- --------- --------- ----------
  n                                21             44             65             65                                 Df = 63   Df = 128
  Total gray matter volume (mL)    733.2 ± 47.1   723.9 ± 53.6   726.9 ± 51.4   756.9 ± 59.5   0.50      \< 0.01   0.68      3.08
  Total white matter volume (mL)   532.5 ± 39.1   520.3 ± 40.5   524.3 ± 40.2   548.2 ± 52.3   0.26      \< 0.01   1.15      2.93
  Cerebrospinal fluid (mL)         331.5 ± 29.5   338.8 ± 36.7   336.4 ± 34.5   340.7 ± 34,3   0.43      0.48      − 0.78    0.71

###### 

Peak voxels in regions of gray matter with significant volumetric differences between KS patients and Controls (p \< 0.05, FWE). L, left; R, right; MNI, Montreal Neurological Institute. Z-value, Inf, infinite.

  Putative region                           Hemisphere   Cluster size (voxel)   MNI peak coordinates (X,Y,Z)   Z-value (peak voxel)
  ----------------------------------------- ------------ ---------------------- ------------------------------ ----------------------
  *KS \< controls*                                                                                             
  Insula                                    L            3133                   − 38,17,− 5                    Inf
  Caudate                                                                       − 15,18,− 8                    Inf
  Putamen                                                                       − 26,8,− 9                     Inf
  Frontal Inf Orb                                                               − 21,12,− 27                   5.66
  Insula                                    R            3503                   38,14,− 5                      Inf
  Putamen                                                                       21.18,− 6                      7.38
  Hippocampus                                                                   24,− 9,− 18                    6.85
  Parahippocampal extending into amygdala                                       22,− 4,− 27                    6.81
  Temporal Pole Sup                                                             27,8,− 27                      6.67
  Frontal Inf Orb                                                               34,23,− 11                     6.11
  Hippocampus extending into amygdala       L            969                    − 20,− 6,− 20                  Inf
  Temporal Pole Sup                         L            67                     − 40,6,− 24                    6.66
  Caudate                                   R            64                     21,− 10,24                     6.36
  Cerebellum                                R            29                     28,− 57,− 32                   5.64
                                                                                                               
  *KS \> controls*                                                                                             
  Postcentral                               R            185                    21,− 40,73                     6.95
  Precuneus                                                                     8,− 46,58                      6.12
  Parietal superior                         R            79                     26,− 49,60                     5.97
  Precuneus                                 L            70                     − 16,− 45,4                    5.65
  Postcentral                               L            53                     − 21,− 43,69                   6.98
  Parietal superior                                                             − 18,− 51,69                   6.62
  Parietal inferior                         L            51                     − 28,− 45,48                   6.92

###### 

Principal component analysis: Domains, tests included and 1.component. WAIS-III, Wechsler Adult Intelligence Scale --- third edition; RCFT, Rey Complex Figure Test and Recognition Trial; RAVLT, Rey Auditory Verbal Learning Test; SCWT, Stroop Color and Word Test; WCST, Winconsin Card Sorting Test; TOL, Tower of London Test.

  Domain                                           Test                                                                                                                        Variability accounted for by 1.component (%)
  ------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  Psychological domain                                                                                                                                                         
   Psychological distress (3 subtests)             SCL-DEP4, SCL-ANX 6, SCL-8                                                                                                  87.5
   Personality (5 subscales from NEO PI-R)         Neuroticism, extraversion, openness, agreeableness, conscientiousness                                                       42.2
   Autism traits (5 subscales from AQ)             Communication, social skills, imagination, attention to detail, attention switching                                         42.4
  Cognitive domain                                                                                                                                                             
   Intelligence (3 subscales)                      Full scale IQ, verbal IQ, performance IQ                                                                                    80.9
   Processing speed (3 subtests)                   WAIS-III C, TMA, TMB                                                                                                        73.9
   Working memory (2 subtests)                     WAIS-III DS, WAIS-III LN                                                                                                    78.7
   Visual performance (3 subtests)                 WAIS-III MR, WAIS-III BD, RCFT copy                                                                                         60.4
   Visual learning and memory (2 subtests)         RCFT immediate recall, RCFT delayed recall                                                                                  95.8
   Verbal learning and memory (3 subscales)        RAVL 1.trail, RAVL total, RAVL delayed recall                                                                               78.2
   Verbal performance (4 subtests)                 Fluency, sentence span, WAIS-III S, WAIS-III V                                                                              71.4
   Response inhibition (1 subtest)                 SCWT diff                                                                                                                   --
   Executive function: planning (2 subscales)      TOL total move score, TOL total correct score                                                                               93.0
   Executive function: flexibility (5 subscales)   WCST cards administered, WCST error(%), WCST persev. responses %, WCST categories completed, WCST failure to maintain set   74.2
